Hormonal therapies such as tamoxifen, or a class of drugs called aromatase inhibitors, can reduce the likelihood that women diagnosed with certain breast cancers will experience a recurrence of their disease. However, a new study finds these treatments — used in breast cancers that are responsive to hormones such as estrogen — are too seldom utilized or often used incorrectly. According to the research team, if all U.S. breast cancer survivors who needed them followed recommendations for hormone therapy, that could mean almost 15,000 lives saved over a decade. Unfortunately, these drugs are “still underused, and in some cases, misused — offered to patients who lack [estrogen] hormone receptors” on their tumor cells, explained study senior author Dr. Dezheng Huo. He’s associate professor of public health sciences at the University of Chicago. Source: HealthDay, February 2, 2017
Attending any of these upcoming events? Have other events to share? Let us know! Email us at NNN@ITCMI.ORG to share your event information or to get on our list serve for event updates.
Request for Concepts: Community-Based Interventions to Address Health Disparities for Indigenous Lung Cancer Patients by the Bristol Myers Squibb Foundation | DUE DATE SEPTEMBER 29, 2023 | LEARN MORE AND REGISTER
GLMA's Annual Conference on LGBTQ+ Health | Applications due by July 30, 2023 | LEARN MORE AND REGISTER